Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ARCpointARCPF -56.33% 3-Year EBITDA Growth Rate is 56.00% as of Dec. 2025, which is 281% above its 10-year median of 14.70. The stock has 6 warning signs investors should review. Among 164 Medical Diagnostics & Research companies, ARCpoint ranks better than 90.85% on this metric.
During the past 12 months, ARCpoint's average EBITDA Per Share Growth Rate was -132.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 56.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of ARCpoint was 56.00% per year. The lowest was -26.60% per year. And the median was 14.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ARCpoint 3-Year EBITDA Growth Rate Related Terms
ARCPF vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, ARCpoint's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARCpoint 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ARCpoint's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where ARCpoint's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 56.00% mean?
ARCpoint (ARCPF) has a 3-Year EBITDA Growth Rate of 56.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ARCpoint and its competitors. This is 281% above median its historical median of 14.70. According to the industry distribution chart, ARCpoint ranks #15 out of 164 companies in the Medical Diagnostics & Research industry, placing it in the top 9.1%.
Is ARCpoint's 3-Year EBITDA Growth Rate too high?
ARCpoint's current 3-Year EBITDA Growth Rate of 56.00% is 281% above median its 10-year median of 14.70. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.30. ARCpoint's value of 56.00% is 395.6% above this industry median. Based on the distribution chart, ARCpoint ranks #15 out of 164 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does ARCpoint's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, ARCpoint ranks #15 out of 164 companies for 3-Year EBITDA Growth Rate. This places ARCpoint in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 11.30. ARCpoint's value of 56.00% is 395.6% above this benchmark. While the company's 10-year median is 14.70 vs. the industry median of 11.30, ARCpoint has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.30, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ARCpoint's current 3-Year EBITDA Growth Rate of 56.00% is 395.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ARCpoint and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ARCpoint's current 3-Year EBITDA Growth Rate is 56.00%, which is 281% above median its own 10-year median of 14.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARCpoint stock overvalued right now?
ARCpoint (ARCPF) has a current 3-Year EBITDA Growth Rate of 56.00%. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 50% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 56.00%, which is 281% above median its 10-year median of 14.70 and 395.6% above the Medical Diagnostics & Research industry median of 11.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For ARCpoint (ARCPF), the current 3-Year EBITDA Growth Rate is 56.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ARCpoint Inc is a U.S-based franchise system providing drug testing, alcohol screening, DNA and clinical lab testing, corporate wellness programs, and employment and background screening, among other services. The platform also digitalizes and streamlines administrative functions such as materials purchasing, compliance, billing, and physician services for ARCpoint franchise labs and other clients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARCPF has been successfully added to your 
